Toward MT-Biomarker-Guided Treatment in Psychosis: A Personalized Medicine Framework Based on Microtubule Dynamic Instability Profiling

Read full text Summarise with VIRAT
Authors: Marko Leicht
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Current antipsychotic treatment operates by trial and error: clinicians cycle through medications until one produces acceptable symptom control with tolerable side effects. This process typically takes months to years and causes significant patient suffering. The microtubule (MT) normalization framework (Leicht, 2026a–d) and the bidirectional disruption model of psychosis suggest a fundamentally different approach. If psychosis results from deviation of microtubule dynamic instability from its optimal range — and if different antipsychotics correct this deviation through distinct MT-modulating mechanisms — then measuring a patient’s individual MT dynamic profile should enable rational, biomarker-guided drug selection. This paper proposes a concrete framework for MT-biomarker-guided treatment in psychosis. Three measurable biomarker axes are identified: (1) the tyrosination/acetylation ratio of α-tubulin, indicating the balance between dynamic and stable MT populations; (2) glutathione (GSH) levels in the medial prefrontal cortex, indicating oxidative tubulin damage; and (3) MAP2 immunoreactivity and phosphorylation state, indicating dendritic MT integrity. Each axis maps onto a specific pole of MT dysfunction (destabilization, over-dynamization, or over-stabilization) and predicts differential response to antipsychotics with distinct MT profiles. The framework is illustrated with a retrospective N=1 case analysis demonstrating concordance between a destabilization-pole clinical history (THC-induced psychosis, amphetamine exposure, sleep deprivation) and differential drug response (therapeutic response to risperidone, paradoxical mania on aripiprazole). If validated prospectively, this framework could transform antipsychotic treatment from empirical trial-and-error into mechanism-based personalized medicine.

Fields of Study & Subjects

Schizophrenia research and treatment Treatment of Major Depression Mental Health and Psychiatry

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
25 March 2026
Language
EN
Document type
Preprint